PROMACTA (eltrombopag olamine)
75 mg/1 · Film-Coated Tablet
By Novartis Pharmaceuticals Corporation
- NDC
- 0078-0687
- Route
- Oral
- Therapeutic class
- Breast Cancer Resistance Protein Inhibitors [MoA], Increased Megakaryocyte Maturation [PE], Increased Platelet Production [PE], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Thrombopoietin Receptor Agonist , Thrombopoietin Receptor Agonists [MoA], UGT1A1 Inhibitors [MoA], UGT1A3 Inhibitors [MoA], UGT1A4 Inhibitors [MoA], UGT1A6 Inhibitors [MoA], UGT1A9 Inhibitors [MoA], UGT2B15 Inhibitors [MoA], UGT2B7 Inhibitors [MoA]
- Marketing category
- NDA
Package sizes
- 30 TABLET, FILM COATED in 1 BOTTLE (0078-0687-15)NDC 0078-0687-15Available to order
Additional information
Full prescribing information for this product is available on request. Submit a sourcing request and our team will share lot details, dating, and current pricing.
Request this medication
Send a request and we'll respond with availability, lot details, and pricing within 2 business hours.
Related in Oncology & Specialty
See all →Verzenio (abemaciclib)
50 mg/1 · Tablet
Eli Lilly and Company
Available to source
Verzenio (abemaciclib)
200 mg/1 · Tablet
Eli Lilly and Company
Available to source
Verzenio (abemaciclib)
100 mg/1 · Tablet
Eli Lilly and Company
Available to source
Verzenio (abemaciclib)
150 mg/1 · Tablet
Eli Lilly and Company
Available to source
